JMI LABS IS NOW PART OF LEARN MORE

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results

In Vitro Activity of Omadacycline and Comparators against Gram-positive and -Negative Isolates Collected from Patients in United States Medical Centers (2018): SENTRY Surveillance Program Results. Lead author: MD Huband presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-540

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018

Update on the In Vitro Activity of Dalbavancin against Indicated Species (Staphylococcus aureus, Enterococcus Faecalis, β-Hemolytic Streptococci, and Streptococcus anginosus Group) Collected from United States Hospitals in 2017-2018. Lead author: HS Sader, presented at ASM Microbe 2019, June 20-24, San Francisco, CA, USA
# Friday-AAR-542

In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program (2017).

In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program (2017). by Pfaller MA, Huband MD, Flamm RK, Bien PA and Castanheira M. published in Antimicrob. Agents Chemother. 2019; 63 (8), e00840

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia.

Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aerugionsa from ICU patients with bloodstream infections or pneumonia. by Shortridge D, Pfaller MA, Arends SJR, Raddatz J, DePestel DD and Flamm RK. published in Open Forum Infect. Dis. 20196 (6): ofz240

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M. published in Diagn. Microbiol. Infect. Dis.: in press, 2020; 96: 114833

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).

Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). by Carvalhaes CG, Sader HS, Flamm RK and Mendes RE. published in J. Antimicrob. Chemother. 2019; 74 (7): 1928-1933

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.

Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017. by Huband MD, Pfaller MA, Shortridge D and Flamm RK. published in J. Glob. Antimicrob. Resist.: in press, 2019.

In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014-2015) in the United States.

In vitro activity of tedizolid in comparison with other oral and intravenous agents against a collection of community-acquired methicillin-resistant Staphylococcus aureus (2014-2015) in the United States. by Pfaller MA, Sader HS, Rhomberg PR, Flamm RK and Mendes RE. published in Microb. Drug Resist. 2019; 25 (6), 938-943

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017). by Pfaller MA, Flamm RK, Duncan LR, Shortridge D, Smart JI, Hamed KA, Mendes RE and Sader HS. published in Diagn. Microbiol. Infect. Dis., 2019; 94 (3): 304-313

Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae, including a challenge set of organisms.

Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae, including a challenge set of organisms. by Arends SJR, Rhomberg PR, Cotroneo N, Rubio A, Flamm RK and Mendes RE. published in Antimicrob. Agents Chemother.: in press, 2019.

Comparative activity of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from United States hospitals.

Comparative activity of ceftazidime-avibactam and ceftolozane-tazobactam against Enterobacteriaceae isolates producing extended-spectrum beta-lactamases from United States hospitals. by Castanheira M, Doyle TB, Mendes RE and Sader HS. published in Antimicrob. Agents Chemother. 2019; 63 (7), e00160

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015).

Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014-2015). by Pfaller MA, Sader HS, Shortridge D, Castanheira M, Flamm RK and Mendes RE. published in J. Chemother. 2019; 13: 1-7

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016).

Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997-2016). by Sader HS, Castanheira M, Arends SJR, Goossens H and Flamm RK. published in J. Antimicrob. Chemother. 2019; 74 (6): 1595-1606

Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents when tested against gram-negative bacterial strains using time-kill curves.

Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents when tested against gram-negative bacterial strains using time-kill curves. by Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ and Shortridge D. published in Antimicrob. Agents Chemother. 2019; 63 (5): e02549

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.

Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. by Carvalhaes CG, Castanheira M, Sader HS, Flamm RK and Shortridge D. Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 93-102

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme.

Activity of ceftolozane-tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the USA and Europe between 2012 and 2016 as part of a global surveillance programme. by Shortridge D, Duncan LR, Pfaller MA and Flamm RK. Int. J. Antimicrob. Agents. 2019; 53 (5): 637-643

In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions.

In vitro activity of plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. by Castanheira M, Davis AP, Serio AW, Krause KM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2019; 94 (1): 73-77.

Characterization of beta-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 REPRISE trial for ceftazidime-avibactam: Correlation of efficacy against beta-Lactamase producers.

Characterization of beta-lactamase content of ceftazidime-resistant pathogens recovered during the pathogen-directed Phase 3 REPRISE trial for ceftazidime-avibactam: Correlation of efficacy against beta-Lactamase producers. By Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK. Antimicrob. Agents Chemother. 63 (6): e02655, 2019.

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2017-2018)

Frequency and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Pneumonia in United States Medical Centers (2017-2018). Lead author: HS Sader, presented at ATS 2019, May 17-22, Dallas, Texas, USA
#8470

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design

Cefepime-Enmetazobactam (formerly AAI101; 30/20 µg) and Cefepime (30 µg) Disk Diffusion Quality Control Ranges Using a CLSI M23 (2018) Multi-Laboratory Study Design. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2778

Evaluation of the Staphylococcus aureus Analysis “1928D” Pipeline to Determine the Epidemiological Threshold Using Whole Genome Sequence Data

Evaluation of the Staphylococcus aureus Analysis “1928D” Pipeline to Determine the Epidemiological Threshold Using Whole Genome Sequence Data. Lead author: LM Deshpande, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2686

Azole Resistance in Candida parapsilosis and Candida tropicalis from a Global Surveillance is Mainly Caused by Alterations in Erg11 and MDR1 Overexpression

Azole Resistance in Candida parapsilosis and Candida tropicalis from a Global Surveillance is Mainly Caused by Alterations in Erg11 and MDR1 Overexpression. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2162

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk

Correlation between Broth Microdilution and Disk Diffusion Methods Results when Testing Ceftaroline against Methicillin-Resistant Staphylococcus aureus Using the 5-µg Ceftaroline Disk. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2783

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae

Synergistic Activity of Colistin and Zidovudine (AZT) Combinations against Colistin-Resistant Enterobacteriaceae. Lead author: LR Duncan, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P2787

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe

In Vitro Activity of BWC0977 (a Novel Bacterial Topoisomerase Inhibitor) and Comparators against Recent Clinical and Molecularly Characterized Enterobacteriaceae and Non-Fermenter Isolates from the United States and Europe. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1847

Antimicrobial Activity of Plazomicin Tested against Enterobacteriaceae Isolates from European Medical Centres Stratified by Infection Type (2014-2017)

Antimicrobial Activity of Plazomicin Tested against Enterobacteriaceae Isolates from European Medical Centres Stratified by Infection Type (2014-2017). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1873

Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide

Antimicrobial Activity of POL7306 Tested against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1843

Plazomicin Activity against Enterobacteriaceae Isolates Carrying Genes Encoding Extended-Spectrum β-Lactamases, Carbapenemases, and/or Aminoglycoside-Modifying Enzymes

Plazomicin Activity against Enterobacteriaceae Isolates Carrying Genes Encoding Extended-Spectrum β-Lactamases, Carbapenemases, and/or Aminoglycoside-Modifying Enzymes. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1872

Activity of Tedizolid and Comparators against Enterococcus spp. that Include Multidrug-Resistant Clinical Isolates from European and US Medical Centres (2016-2018)

Activity of Tedizolid and Comparators against Enterococcus spp. that Include Multidrug-Resistant Clinical Isolates from European and US Medical Centres (2016-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1883

In Vitro Activity of Omadacycline and Comparators against Recent Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results

In Vitro Activity of Omadacycline and Comparators against Recent Gram-Positive and -Negative Clinical Isolates Collected in 2018 from Patients in European Medical Centres: SENTRY Surveillance Program Results. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1876

Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018)

Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018). Lead author: CG Carvalhaes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1882

In Vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecularly Characterized β-Lactamase Genes

In Vitro Activity of the Orally Bioavailable Ceftibuten/VNRX-7145 Combination against a Challenge Set of Enterobacteriaceae Pathogens Carrying Molecularly Characterized β-Lactamase Genes. Lead author: RE Mendes, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1180

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018

Antimicrobial Activity of Cefepime-Zidebactam (WCK 5222) against Clinical Isolates of Carbapenem-Resistant Enterobacterales Collected Worldwide in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1171

Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America in 2015-2016

Antimicrobial Activity of Cefoperazone-Sulbactam Tested against Gram-Negative Organisms from Europe, Asia-Pacific, and Latin America in 2015-2016. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1199

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms

In Vitro Activity of the Extended-Spectrum β-Lactamase Inhibitor Enmetazobactam (formerly AAI101), in Combination with Cefepime, against 90 Moleculary Characterized Enterobacteriaceae Isolates Expressing a Variety of Non-β-Lactam Resistance Mechanisms. Lead author: MD Huband, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1170

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Patients at Risk of Infections Caused by Resistant Gram-Negative Pathogens. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1191

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018)

Antimicrobial Activity of High-Dose Extended-Infusion Cefepime-Tazobactam (WCK 4282) Tested against Gram-Negative Organisms Collected from Medical Centres in Europe and the Asia-Pacific Region (2018). Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1174

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018

Susceptibility Trends of Ceftolozane-Tazobactam and Comparators When Tested against European Gram-Negative Bacterial Surveillance Isolates Collected from 2012-2018. Lead author: D Shortridge, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1189

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018

Cefepime-Zidebactam (WCK 5222) Activity When Tested against Gram-Negative Organisms Isolated from Patients Hospitalized in Europe and the Asia-Pacific Region in 2018. Lead author: HS Sader, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#P1172

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type

Activity of Meropenem-Vaborbactam and Single-Agent Comparators against KPC-Producing Enterobacterales Isolates from European Countries (2016-2018) Stratified by Infection Type. Lead author: M Castanheira, presented at ECCMID 2019, April 13-16, Amsterdam, Netherlands
#L0041

In vitro activity of tedizolid against gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014-2016.

In vitro activity of tedizolid against gram-positive cocci isolates from patients hospitalized with pneumonia in the United States and Europe, 2014-2016. by Bensaci M, Tan C, Pfaller MA and Mendes RE published in Journal Infect Diseases and Treatment. 2018; 4 (1): 2

In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories.

In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories. by Pfaller MA, Rhomberg PR, Wiederhold NP, Gibas C, Sanders C, Fan H, Mele J, Kovanda LL and Castanheira M published in Antimicrob Agents Chemother. 2018; 62 (10): e01230

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016). by Duncan LR, flamm RK, Sader HS and Mendes RE published in Diagn. Microbiol. Infect. Dis.: in press, 2018.

Trends in Antimicrobial Nonsusceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017.

Trends in Antimicrobial Nonsusceptibility of PCV13-Type Streptococcus pneumoniae Pneumonia in Adults in the United States during 2009-2017. Lead author: RE Mendes, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1444

Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam In Vitro Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2017)

Comparison of Ceftazidime-Avibactam and Ceftolozane-Tazobactam In Vitro Activities when Tested against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in US Medical Centers (2017). Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA USA
#2427

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates.

Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Clinical Trial Anaerobic Isolates. Lead author: D Shortridge, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2373

Activity of a Long-Acting Echinocandin Rezafungin Tested against Invasive Fungal Isolates Collected Worldwide

Activity of a Long-Acting Echinocandin Rezafungin Tested against Invasive Fungal Isolates Collected Worldwide. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#2400

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers.

Antimicrobial Activity of Dalbavancin Tested against Gram-Positive Organisms Isolated from Patients with Infective Endocarditis in United States and European Medical Centers. Lead author: HS Sader, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1081

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States.

Comparative Activity of Plazomicin and Other Aminoglycosides against Enterobacteriaceae Isolates from Various Infection Sources from Hospitalized Patients in the United States. Lead author: M Castanheira, presented at IDWeek 2018, October 3-7, San Francisco, CA, USA
#1345